Mwanzo22UA • FRA
add
BioNTech SE
Bei iliyotangulia
€ 115.00
Bei za siku
€ 111.40 - € 115.80
Bei za mwaka
€ 69.70 - € 124.60
Thamani ya kampuni katika soko
28.71B USD
Wastani wa hisa zilizouzwa
elfu 1.19
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.24B | 39.04% |
Matumizi ya uendeshaji wa biashara | 1.04B | 53.43% |
Mapato halisi | 198.10M | 23.35% |
Kiwango cha faida halisi | 15.91 | -11.32% |
Mapato kwa kila hisa | 0.81 | 20.90% |
EBITDA | 65.30M | -30.31% |
Asilimia ya kodi ya mapato | -24.83% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 16.71B | 6.10% |
Jumla ya mali | 22.40B | 0.87% |
Jumla ya dhima | 3.29B | 40.43% |
Jumla ya hisa | 19.11B | — |
hisa zilizosalia | 239.74M | — |
Uwiano wa bei na thamani | 1.44 | — |
Faida inayotokana na mali | 0.23% | — |
Faida inayotokana mtaji | 0.27% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 198.10M | 23.35% |
Pesa kutokana na shughuli | -638.90M | -178.76% |
Pesa kutokana na uwekezaji | -142.10M | 88.47% |
Pesa kutokana na ufadhili | -7.90M | 97.46% |
Mabadiliko halisi ya pesa taslimu | -752.10M | -12.12% |
Mtiririko huru wa pesa | -684.45M | -217.91% |
Kuhusu
BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2008
Tovuti
Wafanyakazi
6,133
